Stock screener

DNLI

Conviction 80HealthcareScan · Fri, Jun 26, 2026
DNLI$25.59+3.48%
ResistanceSupportVol 14
63 bars
Vol MA14 2.04M
Mar 27Apr 15May 4May 20Jun 9Jun 26
Denali Therapeutics Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.denalitherapeutics.com
Price25.59
Change+3.48%
Gap+0.53%
Rel volume2.28×
Avg volume1.94M
Avg $ vol42.86M
SMA 2021.93
SMA 5020.48
SMA 20018.61
Price vs 50+24.97%
Price vs 200+37.52%
MA stackbullish
50/200 cross
Supertrendup · 21.53
RSI (14)76
MACD hist0.41
MACD cross
Stoch %K / %D94 / 88
ADX (14)36
+DI / −DI32 / 7
RSI divergence
MACD divergence
ATR %+4.66%
ADR %5.16%
52w high25.59
52w low12.75
From 52w high+0.00%
Above 52w low+100.71%
New 52w highYes
SqueezeOff
Bollinger width36.51%
%B0.96
Donchian pos94.68%
Donchian high25.97
Donchian low18.92
AVWAP (52w high)25.26
vs AVWAP high+1.32%
AVWAP (52w low)18.92
vs AVWAP low+35.28%
OBV trendUp
Chaikin MF (20)0.03
Today vs 20d2.28×
Avg vol (14d)2.04M
Avg vol (20d)1.94M
Avg $ vol (20d)42.86M
Market cap
RS 3m (vs SPY)-1.74%
RS 6m (vs SPY)+34.33%
RS line new highNo
Trend template7/8
Technical rank92.2
1 week+9.78%
1 month+26.62%
3 months+29.67%
6 months+52.23%
1 year+77.09%
YTD+57.28%
P/E-7.65
P/B4.24
P/S
P/FCF-9.29
EPS-2.97
Div yield
ROE-55.34%
ROA-40.48%
Debt/Eq
Current9.28
EV/EBITDA-6.50
Gross margin
Net margin
Rev growth
EPS growth-21.23%
Price target35.00
Target upside41.61%
Analyst ratingBuy
Institutional105.49%
Ent. value3.53B
Revenue0
Net income-128.45M
Gross profit
Free cash flow-422.1M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out158.71M
Employees507
ListedFri, Dec 8, 2017
Free float
Float %
Short interest
Days to cover
Short volume
Squeeze score
Next earnings
EPS forecast
Last EPS vs est
Last surprise
Setup gradeA
Conviction80 / 100
Pattern quality
Tech rank92.2 / 100
Group rank50 / 100
Status laneNo active setup
Setup direction
Pattern family
Resistance21.14
Support17.91
Days since event
Candle confirm
News sentiment

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in DNLI

All disclosures →
No recent disclosed trades by Congress in DNLI. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in DNLI · 10 buys

InsiderSideShares
Baker Brothers Life Sciences LP
Director · Common Stock · 2026-06-03
Grant6.41K
BAKER JULIAN
Director · Common Stock · 2026-06-03
Grant6.41K
BAKER FELIX
Director · Common Stock · 2026-06-03
Grant6.41K
BAKER JULIAN
Director · Non- Qualified Stock Option (right to buy) · 2026-06-03
Grant19.23K
Baker Bros. Advisors (GP) LLC
Director · Non- Qualified Stock Option (right to buy) · 2026-06-03
Grant19.23K
BAKER BROS. ADVISORS LP
Director · Non- Qualified Stock Option (right to buy) · 2026-06-03
Grant19.23K
BAKER BROS. ADVISORS LP
Director · Non-Qualified Stock Option (right to buy) · 2026-06-03
Grant19.23K
Baker Brothers Life Sciences LP
Director · Non- Qualified Stock Option (right to buy) · 2026-06-03
Grant19.23K
Schenkein David P
Director · Common Stock · 2026-06-03
Grant6.41K
Cook Jennifer E.
Director · Stock Option (right to buy) · 2026-06-03
Grant19.23K

SEC filings

EDGAR filings in DNLI · 2 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.